M. Travis Quigley

M. Travis Quigley has been in the medical industry since 1999, when they began working as a Sarcoma, Phase 1 at the Dana-Farber Cancer Institute. In 2008, they moved to Infinity Pharmaceuticals Inc. as Clinical Development - Oncology. Quigley then transitioned to Foundation Medicine in 2013 as Clinical Development & Operations. In 2015, they were appointed VP, Oncology Clinical Development at bluebird bio. From 2018-2021, Quigley was VP, Clinical Development & Program Leadership at Arcellx, Inc. and most recently, they took on the role of SVP. Head of Clinical Development at K36 Therapeutics, Inc.

M. Travis Quigley attended Villanova University and University of Massachusetts.